Sevoflurane, USP is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. Sevoflurane, USP should be administered only by persons trained in the administration of general anesthesia.
From the U.S. FDA-approved label for Sevoflurane. Full label: DailyMed.
Sevoflurane, USP is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. Sevoflurane, USP should be administered only by persons trained in the administration of general anesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. Since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane, USP should be used.
From the U.S. FDA-approved label for Sevoflurane. Full label: DailyMed.
DOSAGE & ADMINISTRATION The concentration of sevoflurane being delivered from a vaporizer should be known. This may be accomplished by using a vaporizer calibrated specifically for sevoflurane. The administration of general anesthesia must be individualized based on the patient's response.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
Known or suspected genetic susceptibility to malignant hyperthermia (see WARNINGS - Malignant Hyperthermia, CLINICAL PHARMACOLOGY - Pharmacogenomics )., Known or suspected sensitivity to sevoflurane or to other halogenated inhalational anesthetics.
Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.
Risk of Renal Injury Although data from controlled clinical studies at low flow rates are limited, findings taken from patient and animal studies suggest that there is a potential for renal injury which is presumed due to Compound A. Animal and human studies demonstrate that sevoflurane administered for more than 2 MAC,hours and at fresh gas flow rates of < 2 L/min may be associated with proteinuria and glycosuria.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
Clinical Trials Experience Adverse events are derived from controlled clinical studies conducted in the United States, Canada, and Europe. The reference drugs were isoflurane, enflurane, and propofol in adults and halothane in pediatric patients. The studies were conducted using a variety of premedications, other anesthetics, and surgical procedures of varying length.
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
4 products from 3 makers in the NepalDoc medicine catalog use this generic:
| Brand | Composition | Maker | Pack |
|---|---|---|---|
| SEVOFLURANE Solutions | Sevoflurane | Abbott India Ltd. | |
| Sevorane Inhalation | Sevoflurane | Abbott India Ltd. | |
| Sevorane Inhaler | Sevoflurane (99.97%) | Abbott | bottle of 250 ml Inhaler |
| Sevura Inhaler For Inhalation | Sevoflurane (99.97%) | Neon Laboratories Ltd | bottle of 250 ml Inhaler |
Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.
SAFETY AND HANDLING Occupational Caution There is no specific work exposure limit established for sevoflurane. However, the National Institute for Occupational Safety and Health has recommended an 8 hour time-weighted average limit of 2 ppm for halogenated anesthetic agents in general (0.5 ppm when coupled with exposure to N 2 O) (see ADVERSE REACTIONS ).
Storage information from the U.S. FDA-approved label.
Sevoflurane is recorded in the NepalDoc medicine catalog for: General anaesthesia.
For General anaesthesia: Vecuronium.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.
